Cystobactamid off-target profiling reveals favorable safety, superoxide reduction, and SCARB1 inhibition in eukaryotes
Timo Risch, Benedikt Hellwinkel, Dietrich Mostert, Andreas M. Kany, Danny Solga, Tim Seedorf, Dominik Heimann, Jessica Hoppstädter, Daniel Kohnhäuser, Jil-Sophie Hilgers, Franziska Fries, Felix Deschner, Mark Brönstrup, Andreas Kirschning, Stephan A. Sieber, , Rolf Müller
This study profiles cystobactamids' off-target effects in eukaryotes, showing safety, superoxide reduction, and SCARB1 inhibition with therapeutic potential.
npj Drug Discovery. · Aug 6, 2025Peer-reviewedPharmacology & Toxicology